ArticleHealth science reports2025
Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions-A Narrative Review.Health science reports · 2026Article
- Cancer Cytogenetics: Deep Roots, New Branches in the Age of Omics.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Cytogenetic abnormalities at diagnosis are detected in over half of adult patients with acute myeloid leukemia (AML). This study aimed to evaluate the impact of these abnormalities on the outcomes of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in an Iranian cohort. Methods: This retrospective study included 206 AML patients aged over 15 who underwent allogeneic HSCT at a single center. Cytogenetic abnormalities were identified from medical records, and survival outcomes, including overall survival (OS) and leukemia-free survival (LFS), were assessed across different cytogenetic risk groups. Multivariable analyses were adjusted for age, sex, donor type, time from diagnosis to transplant, and disease status at transplant. Results: The median follow-up duration was 46.75 months. 1-, 3-, and 5-year OS rates were 80.0%, 65.9%, and 58.5%, respectively, with significant differences based on cytogenetic risk. Patients with -7, 7q abnormalities, +8, complex karyotype, and monosomal karyotype exhibited shorter OS, classifying them as adverse-risk. Patients with normal karyotype, inversion (16), and t(16;16) were intermediate-risk. LFS at 1, 3, and 5 years was 74.6%, 64.5%, and 54.1%, respectively, with adverse cytogenetic profiles significantly associated with shorter LFS. Conclusions: This study demonstrates the prognostic significance of cytogenetic profiles in Iranian AML patients post-HSCT. Results underscore the importance of cytogenetic stratification in guiding treatment decisions, suggesting that risk-adapted guidelines may benefit specific populations. Future prospective studies on survival outcomes in Iranian AML patients could refine evidence-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.